当前位置: X-MOL 学术Nature › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Nature ( IF 50.5 ) Pub Date : 2021-02-15 , DOI: 10.1038/s41586-021-03326-4
Roberta Zappasodi 1, 2, 3 , Inna Serganova 3, 4 , Ivan J Cohen 4, 5 , Masatomo Maeda 4 , Masahiro Shindo 4 , Yasin Senbabaoglu 1, 6 , McLane J Watson 7 , Avigdor Leftin 8 , Rachana Maniyar 1 , Svena Verma 1, 9 , Matthew Lubin 4 , Myat Ko 4 , Mayuresh M Mane 4 , Hong Zhong 1 , Cailian Liu 1 , Arnab Ghosh 1 , Mohsen Abu-Akeel 1 , Ellen Ackerstaff 8 , Jason A Koutcher 3, 8, 10, 11 , Ping-Chih Ho 12, 13 , Greg M Delgoffe 7 , Ronald Blasberg 4, 10 , Jedd D Wolchok 1, 2, 3, 11, 14 , Taha Merghoub 1, 2, 3, 11, 14
Affiliation  

Limiting metabolic competition in the tumour microenvironment may increase the effectiveness of immunotherapy. Owing to its crucial role in the glucose metabolism of activated T cells, CD28 signalling has been proposed as a metabolic biosensor of T cells1. By contrast, the engagement of CTLA-4 has been shown to downregulate T cell glycolysis1. Here we investigate the effect of CTLA-4 blockade on the metabolic fitness of intra-tumour T cells in relation to the glycolytic capacity of tumour cells. We found that CTLA-4 blockade promotes metabolic fitness and the infiltration of immune cells, especially in glycolysis-low tumours. Accordingly, treatment with anti-CTLA-4 antibodies improved the therapeutic outcomes of mice bearing glycolysis-defective tumours. Notably, tumour-specific CD8+ T cell responses correlated with phenotypic and functional destabilization of tumour-infiltrating regulatory T (Treg) cells towards IFNγ- and TNF-producing cells in glycolysis-defective tumours. By mimicking the highly and poorly glycolytic tumour microenvironments in vitro, we show that the effect of CTLA-4 blockade on the destabilization of Treg cells is dependent on Treg cell glycolysis and CD28 signalling. These findings indicate that decreasing tumour competition for glucose may facilitate the therapeutic activity of CTLA-4 blockade, thus supporting its combination with inhibitors of tumour glycolysis. Moreover, these results reveal a mechanism by which anti-CTLA-4 treatment interferes with Treg cell function in the presence of glucose.



中文翻译:

CTLA-4 阻断导致糖酵解低肿瘤中 Treg 稳定性的丧失

限制肿瘤微环境中的代谢竞争可能会提高免疫治疗的有效性。由于其在活化 T 细胞的葡萄糖代谢中的关键作用,CD28 信号传导已被提议作为 T 细胞1的代谢生物传感器。相比之下,CTLA-4 的参与已被证明可下调 T 细胞糖酵解1。在这里,我们研究了 CTLA-4 阻断对肿瘤内 T 细胞代谢适应度与肿瘤细胞糖酵解能力的影响。我们发现 CTLA-4 阻断促进了代谢适应性和免疫细胞的浸润,特别是在糖酵解低的肿瘤中。因此,用抗 CTLA-4 抗体治疗改善了患有糖酵解缺陷肿瘤的小鼠的治疗结果。值得注意的是,肿瘤特异性 CD8+ T 细胞反应与糖酵解缺陷型肿瘤中肿瘤浸润性调节性 T (T reg ) 细胞对 IFNγ 和 TNF 产生细胞的表型和功能失稳相关。通过在体外模拟高糖酵解肿瘤微环境和低糖酵解肿瘤微环境,我们表明 CTLA-4 阻断对 T reg细胞不稳定的影响取决于 T reg细胞糖酵解和 CD28 信号传导。这些发现表明,减少肿瘤对葡萄糖的竞争可能促进 CTLA-4 阻断剂的治疗活性,从而支持其与肿瘤糖酵解抑制剂的组合。此外,这些结果揭示了抗 CTLA-4 治疗干扰 T reg的机制葡萄糖存在下的细胞功能。

更新日期:2021-02-15
down
wechat
bug